1. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
- Author
-
Shi Yin Wong, Ainsley Ryan Yan Bin Lee, Aaron Hon Jiun Sia, Yu Jun Wo, Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Ching-Ching Ong, Lynette L. Teo, Tiong-Cheng Yeo, Kian-Keong Poh, William K. Kong, Raymond C. Wong, and Ching-Hui Sia
- Subjects
Pharmacology ,Pharmacology (medical) ,General Medicine ,Cardiology and Cardiovascular Medicine - Abstract
Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and heart failure-related hospitalisations. We examined whether and how GLP-1RAs affect cardiac function in cardiovascular and metabolic diseases including type 2 diabetes, heart failure and post-myocardial infarction.In this PRISMA-adherent systematic review and meta-analysis, three databases were searched from inception to July 2021 and registered on PROSPERO (CRD42021259661).20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed. Among type 2 diabetes patients, GLP-1RA resulted in improved systolic function measured by circumferential strain (mean difference [MD]= -5.48; 95% CI: -10.47 to -0.49; P= 0.03; IGLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient's condition.
- Published
- 2022